Immunovant
Preço: 33.62Empresa e modelo de negócios
Immunovant is a biotechnology company focused on developing innovative therapies for autoimmune diseases. Its core product is IMVT-1401, a monoclonal antibody designed to treat conditions such as myasthenia gravis. The company primarily operates in the healthcare sector, with its main revenue source being potential future sales of its therapeutic products. Immunovant is currently in the clinical development stage, with no commercialized products generating revenue.
Perfil de investimento
The investment profile of Immunovant is more aligned with growth investors due to its focus on developing new therapies and the potential for significant future revenue, albeit with high associated risks. The stock may not appeal to dividend or value investors given the lack of current profitability and established revenue streams.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -2.78 Risco
- Surpresa de EPS
- -21.7% pior que o esperado
- Volatilidade 20d
- 8.4% normal
Impacto da previsão
neutroAcompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-13 02:40 | Vender | Manter | Positive momentum, but fundamentals show significant weakness. |
| 2026-06-03 02:43 | Manter | Vender | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-22 02:48 | Vender | Manter | Strong recent performance, but fundamentals remain weak. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-21 10:35 | H.C. Wainwright | Preço-alvo elevado | — → 40 | 35.56 |
| 2026-01-06 12:55 | Wolfe Research | Rating elevado | — → 50 | 24.97 |
| 2025-12-18 13:29 | Guggenheim | Preço-alvo reduzido | 44 → 41 | 26.2689 |
Nada ainda